James Q Del Rosso1, Emil A Tanghetti2, Hilary E Baldwin3, David A Rodriguez4, Ilia L Ferrusi5. 1. JDR Dermatology Research/Thomas Dermatology, Las Vegas, Nevada. 2. The Center for Dermatology and Laser Surgery, Sacramento, California. 3. The Acne Treatment and Research Center, Morristown, New Jersey. 4. Dermatology Associates and Research, Coral Gables, Florida. 5. Allergan plc, Irvine, California.
Abstract
Objective: Evaluate patients' perceptions of rosacea symptoms and treatments. Design: Cross-sectional, web-based survey conducted from May 8 to July 1,2015. Setting: E-mail invitation. Participants: Male and female adults in the United States who self-reported having a physician's diagnosis of rosacea. Measurements: Sociodemographic and clinical characteristics were collected for eligible respondents using the Self-Assessment of Rosacea Facial Redness scale and the Symptom Assessment for Rosacea Facial Bumps and Pimples questionnaire. Respondents were instructed how to differentiate erythematotelangiectatic rosacea and papulopustular rosacea. Use of different treatments and satisfaction with treatment were assessed, as were coping mechanisms. Results: More than 4,000 individuals responded and 600 completed the survey. The participants' mean age was 51.7 years and more than 90 percent rated their rosacea severity as mild or moderate. Most practiced stress and/or anxiety management, used makeup to cover rosacea, used sun protection, and changed their exercise regimens to cope with rosacea flare-ups. Participants reported avoiding sun exposure, hot baths and saunas, and specific skin care products to circumvent potential rosacea flare-ups. More than half (55.7%) had used a prescribed topical agent for rosacea in the preceding month, and 26.3 percent had used a prescribed oral antibiotic. Fewer than half were satisfied with treatment outcomes. Conclusion: Despite the chronic nature of rosacea, participants commonly used prescription agents only to treat flare-ups and relied on sun protection and other avoidance mechanisms to reduce their frequency. Education is needed to communicate the long-term nature of rosacea and the need for continued treatment to maintain long-term control.
Objective: Evaluate patients' perceptions of rosacea symptoms and treatments. Design: Cross-sectional, web-based survey conducted from May 8 to July 1,2015. Setting: E-mail invitation. Participants: Male and female adults in the United States who self-reported having a physician's diagnosis of rosacea. Measurements: Sociodemographic and clinical characteristics were collected for eligible respondents using the Self-Assessment of Rosacea Facial Redness scale and the Symptom Assessment for Rosacea Facial Bumps and Pimples questionnaire. Respondents were instructed how to differentiate erythematotelangiectatic rosacea and papulopustular rosacea. Use of different treatments and satisfaction with treatment were assessed, as were coping mechanisms. Results: More than 4,000 individuals responded and 600 completed the survey. The participants' mean age was 51.7 years and more than 90 percent rated their rosacea severity as mild or moderate. Most practiced stress and/or anxiety management, used makeup to cover rosacea, used sun protection, and changed their exercise regimens to cope with rosacea flare-ups. Participants reported avoiding sun exposure, hot baths and saunas, and specific skin care products to circumvent potential rosacea flare-ups. More than half (55.7%) had used a prescribed topical agent for rosacea in the preceding month, and 26.3 percent had used a prescribed oral antibiotic. Fewer than half were satisfied with treatment outcomes. Conclusion: Despite the chronic nature of rosacea, participants commonly used prescription agents only to treat flare-ups and relied on sun protection and other avoidance mechanisms to reduce their frequency. Education is needed to communicate the long-term nature of rosacea and the need for continued treatment to maintain long-term control.
Authors: Joseph Fowler; Mark Jackson; Angela Moore; Michael Jarratt; Terry Jones; Kappa Meadows; Martin Steinhoff; Diane Rudisill; Matthew Leoni Journal: J Drugs Dermatol Date: 2013-06-01 Impact factor: 2.114
Authors: James Q Del Rosso; Diane Thiboutot; Richard Gallo; Guy Webster; Emil Tanghetti; Lawrence F Eichenfield; Linda Stein-Gold; Diane Berson; Andrea Zaenglein Journal: Cutis Date: 2014-03
Authors: Martin Schaller; Thomas Dirschka; Sol-Britt Lonne-Rahm; Giuseppe Micali; Linda F Stein Gold; Jerry Tan; James Del Rosso Journal: Acta Derm Venereol Date: 2021-10-31 Impact factor: 3.875
Authors: Joshua A Zeichner; Lawrence F Eichenfield; Steven R Feldman; J Scott Kasteler; Ilia L Ferrusi Journal: J Clin Aesthet Dermatol Date: 2018-02-01
Authors: L F Eichenfield; J Q Del Rosso; J K L Tan; A A Hebert; G F Webster; J Harper; H E Baldwin; L H Kircik; L Stein-Gold; A Kaoukhov; N Alvandi Journal: Br J Dermatol Date: 2019-02-27 Impact factor: 9.302